| Patient | Voltaire |
|---|---|
| Date of birth | 1942-11-21 |
| Identifiers | MRN HR-EN002-SYN; SSN (made up) 000-02-5174 |
| Document date | 2026-04-13 |
| Author | Honorine Delacroix-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
One-week review of CT urography and kidney function; urology consultation and office cystoscopy today. [S]
Voltaire returns one week after his first visit, with the catheter in place since then. The urine in the bag has gone from red to light pink, with one small clot four days ago and none since. He has had no fever, flank pain, or bladder spasm, and the catheter has drained without blockage. He stopped the diphenhydramine and the phosphate enemas; he slept poorly for two nights and now sleeps about five hours. His bowels open every one to two days on polyethylene glycol. He takes tamsulosin each evening without dizziness. He has cut his coffee to about five cups a day. The CT urography and chest CT were done two days after the first visit. He saw Dr. Bergström-Nwosu of urology this morning, who performed a flexible cystoscopy. [S]
| Element | Detail |
|---|---|
| Bleeding | Light pink urine; one small clot four days ago |
| Catheter | 16 Fr indwelling catheter draining well; no fever or spasm |
| Medicines | Diphenhydramine and phosphate enemas stopped; tamsulosin tolerated; polyethylene glycol continued |
| Imaging | CT urography and chest CT done two days after intake |
| Cystoscopy | Done by urology this morning |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or sweats; appetite small but steady |
| Genitourinary | Positive | Light pink urine through the catheter; no flank pain, spasm, or leakage |
| Gastrointestinal | Negative | Bowels open every one to two days; no abdominal pain |
| Respiratory | Negative | No cough or blood in the sputum |
| Cardiovascular | Negative | No dizziness on standing |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Diphenhydramine 25 mg oral capsule, one capsule at night for sleep (over the counter) | One capsule at bedtime | Oral route | 2025-09-01 to 2026-04-06 | stopped | S |
| Tamsulosin 0.4 mg oral capsule, one capsule at bedtime | One capsule 30 minutes after the evening meal | Oral route | 2026-04-06 | active | S |
| Polyethylene glycol 3350, 17 g in a glass of water once daily | 17 g dissolved in water once daily | Oral route | 2024-01-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-13 | Body height | 170 | cm | S |
| 2026-04-13 | Body weight | 54 | kg | S |
| 2026-04-13 | Body mass index (BMI) [Ratio] | 18.7 | kg/m2 | S |
| 2026-04-13 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-04-13 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-04-13 | Heart rate | 80 | /min | S |
| 2026-04-13 | Respiratory rate | 16 | /min | S |
| 2026-04-13 | Body temperature | 36.6 | Cel | S |
| 2026-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-13 | Hemoglobin [Mass/volume] in Blood | 11.2 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-13 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 8-24 mg/dL | Normal | S |
| 2026-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.24 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 58 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
Vital signs recorded on 2026-04-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, alert, and lively |
| Cardiovascular | Blood pressure 132/70 mmHg seated and 128/68 mmHg standing; heart rate 80, regular |
| Abdomen | Soft and non-tender; bladder not palpable |
| Genitourinary | Catheter draining light pink urine without clots; meatus clean |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Visible blood in the urine for three weeks with clots, and a weak stream, straining, and frequent small voids, in a man of 83; under evaluation | active | confirmed | R31.0 | S — Synthetic presenting problem echoing his documented urinary complaints and last illness; superseded by the diagnosis at the third chronic-care visit. |
| Chronic urinary retention with overflow (post-void residual 460 mL at intake), worsened by a nightly anticholinergic sleep aid; drained by an indwelling catheter | active | confirmed | R33.8 | S — Synthetic finding echoing the strangury and catheterization documented in his last weeks. |
| Acute kidney injury from bladder outlet obstruction (creatinine 1.68 mg/dL, from 1.1 mg/dL a year earlier) | resolved | confirmed | N17.9 | S — Synthetic finding; it echoes, without asserting, the later encyclopedia term uremia. |
| Benign prostatic hyperplasia with lower urinary tract symptoms: prostate about 78 mL on CT, enlarged, firm, and smooth on examination, PSA 6.4 ng/mL with a PSA density of 0.08; no prostate biopsy, by shared decision | active | confirmed | N40.1 | S — Synthetic diagnosis echoing the very large prostate described at the 1778 autopsy; whether that prostate was malignant is unknown (CLM-0012). |
| Chronic constipation, lifelong by his account, with long use of laxatives and self-given enemas | active | confirmed | K59.09 | S — Synthetic modern problem echoing his documented colic, purges, and enemas; no diagnosis of inflammatory bowel disease is made. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Upper-tract imaging: multiphasic CT urography, with chest CT | Once, in the initial evaluation of gross hematuria | Completed today | Done two days after intake and reviewed today: bladder mass with possible extravesical extension, clear upper tracts, no nodes; chest clear |
| Examination | Cystoscopy | Once, in the initial evaluation of gross hematuria | Completed today | Flexible cystoscopy by urology today: 4 cm solid sessile tumor of the posterior wall and dome |
| Laboratory | Urine culture and urine cytology | Once, in the initial evaluation of gross hematuria (cytology for gross hematuria by expert consensus) | Completed today | Results from the first visit reviewed today: culture no growth; cytology atypical squamous cells suspicious for malignancy |
| Laboratory | Kidney function and potassium after relief of obstruction | Within one to two weeks of catheter drainage | Completed today | Creatinine 1.24 mg/dL (eGFR 58), BUN 22 mg/dL, potassium 4.6 mmol/L; recovered |
| Laboratory | Hemoglobin during gross hematuria | At each visit while bleeding continues | Completed today | 11.2 g/dL, stable from 11.6 |
| Laboratory | PSA interpretation | Once, when it would change management | Completed today | 6.4 ng/mL with a prostate of about 78 mL (density 0.08); no MRI or biopsy by shared decision |
| Survey | IPSS | Baseline and at every follow-up visit (CMID BPH) | Not indicated | Not scored while the catheter drains the bladder; 22 at intake before the catheter; next after the trial without catheter |
| Examination | Post-void residual | At baseline when retention is suspected, after a trial without catheter, and when symptoms change | Not indicated | Catheter in place; 460 mL at intake; repeat after the trial without catheter |
| Examination | Digital rectal examination | Baseline, then as clinically indicated | Up to date | Done at intake: enlarged, firm, smooth, no discrete nodule |
| Medication safety | Alpha-blocker tolerability (orthostatic blood pressure, dizziness) | At 4 to 12 weeks after starting, and at each visit in a frail older adult | Completed today | No postural drop (132/70 to 128/68 mmHg); no dizziness |
| Medication safety | Medication review for drugs that worsen retention or kidney function | At intake and at each change | Completed today | Diphenhydramine and sodium phosphate enemas stopped; no NSAIDs; no other anticholinergics |
| Self-management | Catheter care | While a catheter is in place | Completed today | Leg and night bags, hand hygiene, bag below the bladder, fluids 1.5 to 2 liters a day |
| Referral | Urology consultation | For gross hematuria and for retention with kidney injury | Completed today | Seen today; resection booked in two days |
Goal progress:
Guideline basis: Microhematuria: AUA/SUFU Guideline (2020; amended 2025) (2025); Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024) (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2026 (including non-urothelial histologies) (2026); EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer (2026); Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023 (2023); Diagnosis, Prevention, and Treatment of Catheter-Associated Urinary Tract Infection in Adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America (2009); American Geriatrics Society 2023 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2023); Prostate Cancer: Screening (2018); CMID: Clinical Monitoring Intelligence Database, urologic cancer and benign prostatic hyperplasia monographs (2026)
Follow-up: Resection in two days; chronic-care review with the pathology in about ten days; sooner for clots, a blocked catheter, or fever. Next scheduled visit 2026-04-22: review of resection pathology, diagnosis, geriatric assessment, trial without catheter, and shared decision on treatment. [S]